Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Five9 Inc (FIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Five9 Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Five9 Inc trades at $24.13 (market cap $1.91B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.4× Five9 Inc's market cap. Which is the better fit depends on your goals.
| ACAD | FIVN | |
|---|---|---|
Market Cap | $4.49B | $1.91B |
Sector | Health | Technology |
52-Week High | $28.06 | $29.16 |
52-Week Low | $20.06 | $13.61 |
Enterprise Value | $3.69B | $1.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Five9 (FIVN) trades at $24.99, up 6.59% today, showing strong momentum after consistently beating earnings estimates. The stock maintains bullish technical signals with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Revenue growth has accelerated from $779M in 2022 to $1.15B in 2025, with the company achieving profitability for the first time in 2025 with $39M net income. Recent leadership appointments and AI product launches signal continued innovation in the CX platform space.
The outlook remains positive with 61% analyst buy ratings and a $27 consensus target offering 8% upside. Key catalysts include sustained revenue growth and margin expansion, while risks involve ongoing fiduciary investigations and competitive pressures in the cloud contact center market. The stock's premium valuation (P/E 37.1) requires continued execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
